億勝生物科技(01061.HK):不含防腐劑單劑量鹽酸莫西沙星滴眼液在中國內地獲批上市
格隆匯4月7日丨億勝生物科技(01061.HK)宣佈,公司間接全資附屬珠海億勝生物製藥已取得國家藥監局批准於中國內地註冊及商業化不含防腐劑單劑量鹽酸莫西沙星滴眼液(“獲批准產品”)。獲批准產品為首款獲批的不含防腐劑單劑量鹽酸莫西沙星滴眼液,用於治療敏感微生物引起的細菌性結膜炎。
董事會相信,作為集團第五款單劑量滴眼液產品,獲批准產品將增強集團於眼科的競爭力及領導地位。集團其他四款不含防腐劑單劑量滴眼液產品為妥布黴素滴眼液、左氧氟沙星滴眼液、玻璃酸鈉滴眼液及貝復舒(rb-bFGF)滴眼液。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.